Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Perillyl alcohol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NEO100 Phase 1 | EXPERIMENTAL | Intranasal delivery of NEO100 (perillyl alcohol) four times a day, escalation up to four different doses to determine maximum tolerated dose. |
| NEO100 Phase 2A | EXPERIMENTAL | Intranasal delivery of NEO100 (perillyl alcohol) four times a day. Treatment of total of 25 patients at maximum tolerated dose. |
| Name | Type | Description |
|---|---|---|
| Perillyl alcohol | DRUG | Intranasal administration |
Inclusion Criteria To be eligible to participate in the study, a patient must meet all of the following inclusion criteria: * Patient must have radiographically-confirmed progression of, or recurrent, primary or secondary Grade IV glioma, including infratentorial (brainstem, cerebellar) glioma (co...
Perillyl alcohol is an investigational small molecule being studied for the treatment of Glioblastoma Multiforme, specifically in recurrent or progressive Grade III or IV IDH1 mutated glioma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
Perillyl alcohol targets the Ras protein, a molecular target involved in cell signaling pathways. By inhibiting Ras, the drug aims to interfere with tumor growth and progression in Glioblastoma Multiforme. This mechanism is being evaluated in an ongoing Phase 1 clinical trial.
Perillyl alcohol is being developed by NeOnc Technologies Holdings, Inc., a biopharmaceutical company. The company is conducting clinical research on this small molecule for the treatment of Glioblastoma Multiforme. NeOnc Technologies Holdings, Inc. is the sponsor of the ongoing Phase 1 trial.
Perillyl alcohol is currently in Phase 1 clinical development. It is an investigational drug being studied for Glioblastoma Multiforme and has not yet received FDA approval. The drug is being evaluated in an active clinical trial that is not recruiting new participants.
Perillyl alcohol is being studied in clinical trial NCT02704858, titled 'Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma'. This Phase 1 trial is active but not recruiting, with an enrollment of 49 participants in the United States.
Perillyl alcohol is also known as NEO100, a name used in some contexts for this investigational small molecule. The drug is being developed by NeOnc Technologies Holdings, Inc. for the treatment of Glioblastoma Multiforme and is currently in Phase 1 clinical trials.